| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-03-03 |
| タイトル |
|
|
タイトル |
Final Results of a Multicenter Prospective Study of Stereotactic Body Radiation Therapy for Previously Untreated Solitary Primary Hepatocellular Carcinoma(The STRSPH Study) |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 著者 |
Naoko, Sanuki
Tomoki, Kimura
Atsuya, Takeda
Keisuke, Ariyoshi
Shunsuke, Oyamada
Takuhiro, Yamaguchi
Yuichiro, Tsurugai
Yoshiko, Doi
Masaki, Kokubo
Toshiyuki, Imagumbai
Norio, Katoh
Takahisa, Eriguchi
Satoshi, Ishikura
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Purpose: To report final results of a prospective study of stereotactic body radiation therapy (SBRT) in patients with previously untreated solitary primary hepatocellular carcinoma (HCC).
Methods and Materials: This prospective, single-arm, multicenter phase 2 trial recruited patients with HCC who were unsuitable for, or refused, surgery and radiofrequency ablation, with 3-year overall survival rates as the primary endpoint and survival outcomes and adverse events as secondary endpoints. The prescribed SBRT dose was 40 Gy in 5 fractions. The final data were analyzed in November 2022.
Results: Between 2014 and 2018, 36 patients (median age, 73.5 years) were registered; enrollment was closed before full recruitment due to slow accrual. Overall, 34 patients were analyzed for efficacy evaluation after excluding 2 patients. The median tumor size was 2.3 cm. The median follow-up times for all patients and for survivors were 49 and 56 months, respectively. The 3-year overall survival rate was 82% (95% confidence interval, 65%-92%). The 3-year local control rate was 93% (95% confidence interval, 76%-98%). Grade 3 or higher SBRT-related nonlaboratory toxicities were observed in 4 patients (11%). No grade 5 adverse events were observed.
Conclusions: Final results of this phase 2 trial suggest the efficacy and safety of SBRT for newly diagnosed early-stage HCC that is unfit for other local therapies. Although this study was underpowered by the small number of registrations, the excellent results indicate that SBRT may be an alternative option for the management of early-stage HCC. |
|
言語 |
en |
| bibliographic_information |
en : International Journal of Radiation Oncology Biology Physics
巻 121,
号 4,
p. 942-950,
発行日 2025-03-15
|
| item_11_source_id_7 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1879-355X |
| item_11_relation_11 |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1016/j.ijrobp.2024.10.040 |
| 権利 |
|
|
言語 |
en |
|
権利情報 |
© 2024 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 出版者 |
|
|
出版者 |
Elsevier Inc. |
|
言語 |
en |
International Journal of Radiation Oncology-Biology -Physics_121_4_942.pdf (517 KB)
.png)
